Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 9989.HK Stock
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Price Chart
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 9989.HK Financial and Trading Overview
Contents
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Price Chart
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 9989.HK Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Q&A For Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Stock
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stock price | 2.8 HKD |
Previous Close | 4.46 HKD |
Open | 4.43 HKD |
Bid | 4.41 HKD x N/A |
Ask | 4.49 HKD x N/A |
Day's Range | 4.41 - 4.55 HKD |
52 Week Range | 4.31 - 7.49 HKD |
Volume | 1.31M HKD |
Avg. Volume | 516.17K HKD |
Market Cap | 16.61B HKD |
Beta (5Y Monthly) | 0.360616 |
PE Ratio (TTM) | 10.5 |
EPS (TTM) | -0.58 HKD |
Forward Dividend & Yield | 0.11 (2.56%) |
Ex-Dividend Date | May 24, 2023 |
1y Target Est | 8.35 HKD |
9989.HK Valuation Measures
Enterprise Value | 9.87B HKD |
Trailing P/E | 10.5 |
Forward P/E | 4.8461537 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.5353105 |
Price/Book (mrq) | 0.52288353 |
Enterprise Value/Revenue | 1.508 |
Enterprise Value/EBITDA | 9.301 |
Trading Information
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.360616 |
52-Week Change | -32.32% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.49 HKD |
52 Week Low | 4.31 HKD |
50-Day Moving Average | 4.88 HKD |
200-Day Moving Average | 5.38 HKD |
9989.HK Share Statistics
Avg. Volume (3 month) | 516.17K HKD |
Avg. Daily Volume (10-Days) | 329.3K HKD |
Shares Outstanding | 220.09M |
Float | 478.84M |
Short Ratio | N/A |
% Held by Insiders | 5.73% |
% Held by Institutions | 6.85% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.1 |
Trailing Annual Dividend Yield | 2.24% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.0922 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 8.52% |
Operating Margin (ttm) | 12.31% |
Gross Margin | 33.17% |
EBITDA Margin | 16.20% |
Management Effectiveness
Return on Assets (ttm) | 2.47% |
Return on Equity (ttm) | 4.50% |
Income Statement
Revenue (ttm) | 6.55B HKD |
Revenue Per Share (ttm) | 4.46 HKD |
Quarterly Revenue Growth (yoy) | -31.90% |
Gross Profit (ttm) | N/A |
EBITDA | 1.06B HKD |
Net Income Avi to Common (ttm) | 558.67M HKD |
Diluted EPS (ttm) | 0.42 |
Quarterly Earnings Growth (yoy) | -71.70% |
Balance Sheet
Total Cash (mrq) | 3.08B HKD |
Total Cash Per Share (mrq) | 2.1 HKD |
Total Debt (mrq) | 6.32B HKD |
Total Debt/Equity (mrq) | 50.65 HKD |
Current Ratio (mrq) | 2.415 |
Book Value Per Share (mrq) | 8.434 |
Cash Flow Statement
Operating Cash Flow (ttm) | -969212928 HKD |
Levered Free Cash Flow (ttm) | -1681800192 HKD |
Profile of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Country | Hong Kong |
State | N/A |
City | Shenzhen |
Address | No. 21 Langshan Road |
ZIP | 518057 |
Phone | 86 755 2698 0200 |
Website | https://www.hepalink.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 2366 |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Q&A For Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Stock
What is a current 9989.HK stock price?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 9989.HK stock price today per share is 2.8 HKD.
How to purchase Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stock?
You can buy 9989.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shenzhen Hepalink Pharmaceutical Group Co., Ltd.?
The stock symbol or ticker of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is 9989.HK.
Which industry does the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. company belong to?
The Shenzhen Hepalink Pharmaceutical Group Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. have in circulation?
The max supply of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. shares is 4.47B.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. PE Ratio is now.
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. EPS is -0.58 HKD over the trailing 12 months.
Which sector does the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. company belong to?
The Shenzhen Hepalink Pharmaceutical Group Co., Ltd. sector is Healthcare.